Ovarian Cancer: Even Patients with New Infection benefit from Olaparib

被引：0
|
作者：
Lichert, Frank
机构：
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2019年 / 79卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：322 / 323
页数：2
相关论文
共 50 条
  • [41] BIOANALYTICAL METHOD VALIDATION FOR THERAPEUTIC DRUG MONITORING OF OLAPARIB IN PATIENTS WITH OVARIAN CANCER
    Lewandowski, Konrad
    Karbownik, Agnieszka
    Czyrski, Andrzej
    Urjasz, Hanna
    Stanislawiak-Rudowicz, Joanna
    Grzeskowiak, Edmund
    Szalek, Edyta
    ACTA POLONIAE PHARMACEUTICA, 2024, 81 (02): : 263 - 278
  • [42] Exposure–Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer
    Ma Ida Mohmaed Ali
    Maaike A. C. Bruin
    Vincent O. Dezentjé
    Jos H. Beijnen
    Neeltje Steeghs
    Alwin D. R. Huitema
    Pharmaceutical Research, 2023, 40 : 1239 - 1247
  • [43] Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer EDITORIAL COMMENT
    不详
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2019, 74 (02) : 86 - 87
  • [44] Centralization of ovarian cancer surgery: Do patients benefit?
    Ghaemmaghami, F.
    Hassanzadeh, M.
    Karimi-Zarchi, M.
    Modari-Gilani, M.
    Behtash, N.
    Mousavi, A.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2010, 31 (04) : 429 - 433
  • [45] Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
    Shibani Nicum
    Naomi McGregor
    Rachel Austin
    Linda Collins
    Susan Dutton
    Iain McNeish
    Rosalind Glasspool
    Marcia Hall
    Rene Roux
    Agnieszka Michael
    Andrew Clamp
    Gordon Jayson
    Rebecca Kristeleit
    Susana Banerjee
    Anita Mansouri
    British Journal of Cancer, 2024, 130 : 941 - 950
  • [46] A PILOT INTEGRATED ANALYSIS OF LONG-TERM BENEFIT OF OLAPARIB IN OVARIAN CANCER: RESULTS OF FEASIBILITY TESTING.
    Lheureux, S.
    Ledermann, J.
    Kaye, S.
    Gourley, C.
    Friedlander, M.
    Bowtell, D.
    De Greve, J.
    DeFazio, A.
    Frommer, R.
    De Bono, J. S.
    Audeh, M. W.
    Kohn, E.
    Alsop, K.
    Scott, C.
    Matulonis, U.
    Kaufman, B.
    Burger, B.
    Robertson, J.
    Ho, T.
    Oza, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 141 - 142
  • [47] IDENTIFICATION OF THE POPULATION OF PATIENTS WITH HIGH-GRADE SEROUS OVARIAN CARCINOMA WHO BENEFIT FROM OLAPARIB IN A MEDIUM-SIZED HOSPITAL
    Kumagai, K.
    Sakai, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 743 - 743
  • [48] Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
    Nicum, Shibani
    Mcgregor, Naomi
    Austin, Rachel
    Collins, Linda
    Dutton, Susan
    Mcneish, Iain
    Glasspool, Rosalind
    Hall, Marcia
    Roux, Rene
    Michael, Agnieszka
    Clamp, Andrew
    Jayson, Gordon
    Kristeleit, Rebecca
    Banerjee, Susana
    Mansouri, Anita
    BRITISH JOURNAL OF CANCER, 2024, 130 (06) : 941 - 950
  • [49] Benefit patients with relapse ovarian cancer from suboptimal debulking? Results from a prospective study
    Ibanez, B. Gil
    Oskay-Oeezcelik, G.
    Richter, R.
    Neumann, U.
    Neuhaus, P.
    Lichtenegger, W.
    Sehouli, J.
    ONKOLOGIE, 2010, 33 : 110 - 110
  • [50] Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
    Freyer, Gilles
    Floquet, Anne
    Tredan, Olivier
    Carrot, Aurore
    Langlois-Jacques, Carole
    Lopez, Jonathan
    Selle, Frederic
    Abdeddaim, Cyril
    Leary, Alexandra
    Dubot-Poitelon, Coraline
    Fabbro, Michel
    Gladieff, Laurence
    Lamuraglia, Michele
    NATURE COMMUNICATIONS, 2024, 15 (01)
12345